

Table I. Relationship between p16 expression and clinicopathologic parameters in colorectal cancer.

Clinicopathologic parameter	Labelling index of p16 staining (%)		
	Group A <sup>a</sup>	Group B <sup>b</sup>	Group C <sup>c</sup>
Gender			
Male	5	27	1
Female	5	16	1
Site			
Colon	6	23	1
Rectum	4	20	1
Dukes'			
A, B	8	21	1
C, D	2 <sup>d</sup>	22	1
Histological type			
Well	6	22	0
Moderate/poor	4	21	2
Nodal involvement <sup>e</sup>			
Negative	10	21	1
Positive	0	22	1
Depth of invasion			
~mp	4	14	0
ss~	6	29	2
Distant metastasis			
Negative	8	41	2
Positive	2	2	0
Age (years)	56.7±13.1	62.6±10.3	60.5±20.5
Size (cm) <sup>f</sup>	3.5±1.8	4.8±2.2	8.1±1.6

<sup>a</sup>More than 50% of the cancer cells positive for p16. <sup>b</sup>Ten to 50% of the cells positive. <sup>c</sup>Less than 10% of the cells positive. <sup>d</sup>These 2 cases had no lymph node metastasis but displayed distant metastasis. <sup>e</sup>p=0.003. <sup>f</sup>p=0.048. mp, muscularis propria; ss, subserosa.

yielded no staining in the samples and the HBL100 cells displayed a positive staining and the T98G cells had no staining (data not shown).

In total, 55 paired samples were immunohistochemically stained with the anti-p16 antibody. In the normal colonic mucosa, clear nuclear p16 was detected only occasionally and the LI was <5% in all 55 cases tested (data not shown). In contrast, p16 was abundantly expressed in the majority of CRC tissues, and was localized in the nuclei and cytoplasm. When CRC cases were classified into three groups according to their LI, 10 cases (19%) were classified into group A (LI >50%), 43 (77%) into group B (LI 10-50%) and 2 (4%) into group C (LI <10%). In at least 53 cases (96%), over-expression of p16 was noted in CRC tissue when compared to the corresponding non-neoplastic mucosa. In the 21 CRC tissues utilized for methylation assay, the results of p16 staining correlated well with p16 mRNA expression (data not shown).

*Relationship between p16<sup>INK4</sup> expression and clinicopathologic parameters.* The relationship between the level of staining of p16 in CRC samples and several clinicopathologic parameters was examined. These parameters included gender, tumor site, disease stage, histological grade, lymph node metastasis, depth of invasion, distant metastasis, age and size (Table I). High p16 expression level was associated with a low incidence of lymph node metastasis (group A vs. group B and C, p=0.003), and p16 expression was associated with small tumor size (p=0.048). There was no correlation between p16 expression and other clinicopathologic parameters.

## Discussion

Dysregulation of CKIs, negative regulators of the cell cycle, is often found in human malignancies. The expression of p21<sup>Waf1</sup> is reduced in aberrant crypt foci with dysplasia and carcinomas of the colon and its high expression is related to a better prognosis in gastric cancer (39-41). A decrease in p27<sup>Kip1</sup> is associated with poor prognosis or high grade tumors in various types of human cancer (29,42). Loss or decreased expression of p16 is found in a subset of primary cancers (8-12). These lines of evidence indicate that inactivation of CKI may play a role in carcinogenesis and/or tumor progression of various types of human cancers. However, it appears to be unlikely that loss of p16 plays a central role in tumorigenesis of the colorectum *in vivo*. In this study we found that p16 gene expression was often upregulated in primary CRC tissues compared with non-neoplastic mucosa at both the mRNA and protein levels, though p16 mRNA was lost in most CRC cell lines. These findings are consistent with previous reports (15,24,25) and suggest that the regulatory mechanism of p16 gene expression may be quite distinct between cell lines and *in vivo* tissues of the colorectum.

Loss of p16 mRNA in CRC cell lines is understandable since a band corresponding to the methylated p16 gene was generally present in all CRC cell lines, and hypermethylation, as well as gene alterations, is known to be a major mechanism for inactivation of p16 gene transcription (13,14). On the other hand, a methylated p16 band was detected in 42.9% (9/21) of surgically resected CRC tissues, consistent with other reports that p16 methylation is present in 29-55% of CRC tissues (18-22). However, unlike cell lines, such methylation-positive CRC tissues frequently still expressed p16 mRNA. One clue to explain the differential regulatory mechanisms between CRC cell lines and CRC tissues may be methylation density in the p16 promoter region, rather than the presence of methylation *per se* (26,27). In support of this hypothesis on regulation of the p16 transcript, even cell lines exhibited varying extent of p16 methylation, which could affect p16 gene expression (38,43). We also confirmed that the HCT116 cell line whose one allele of p16 is methylated and silenced and the other is mutated and unmethylated (44), did display both a methylated and an unmethylated p16 band, leading to only modest expression of p16 mRNA (Fig. 2). Other CRC cell lines displaying only the methylated p16 band (MI: 100%) exhibited no p16 mRNA expression. Although methylation density of the p16 gene has been measured in several tumor cell lines, the extent of methylation in CRC tissues has yet not been clarified.

We performed quantitative MSP, using CRC tissues that exhibited p16 gene methylation. Our findings showed that there was a significant decrease in p16 mRNA level in the high-methylation group compared to the no-methylation or low-methylation groups (Fig. 6C). These findings suggest that a hyper-methylation density would facilitate transcriptional repression of the p16 gene in CRC tissues, but that low-methylation may only partially repress p16 gene expression. It was of interest that MI was variable (range: 0.28-0.91) and this could be a characteristic of *in vivo* p16 gene methylation. Concordant p16 expression at protein and RNA level (Fig. 7) suggest that p16 expression may be regulated at transcriptional level. Immunohistochemistry revealed that low level of the p16 protein represented reduced expression within neoplastic epithelium, but not in stromal cells (Fig. 8). In the no-methylation group, CRC tissues exhibited a wide range of p16 mRNA levels (Fig. 6C). This suggests that the basal p16 mRNA level could be also variable in the methylation-positive group, and therefore p16 expression level may not be determined by methylation extent alone. This might account for a few exceptional CRC samples that expressed some p16 mRNA even with the highest MI (0.91) or displayed relatively low p16 mRNA expression despite a low MI (0.29, 0.3) (Fig. 6B).

It remains controversial whether p16 expression is predictive of clinical events. Inactivation of the p16 gene is associated with aggressive disease phenotype including lymph node metastasis, shorter survival in esophageal cancer and advanced stage of hepatocellular carcinomas (45,46). Conversely, it has been reported that high levels of p16 are associated with poor prognosis in carcinomas of the ovary, prostate, and breast (47-49). In the latter tumor types, increased p16 expression might in turn reflect upregulated activity of the cell cycle positive regulators. Our immunohistochemical analysis showed that low p16 expression in CRC tissues correlated with larger tumor size and lymph node metastasis. Other investigators have also shown that p16 expression in CRC tissues was associated with low proliferative activity (24,25) and hypermethylation of the p16 gene was associated with advanced tumor stage and shorter survival (20,22). Taken together, these findings suggest that p16, despite its upregulation, may act as a tumor suppressor gene in CRC tissues, and it is likely that methylation would at least in part contribute to reduction in p16 expression, resulting in facilitation of tumor expansion and enlargement of CRC.

Overexpression of the p16 tumor suppressor gene in CRC tissues appeared to be paradoxical and we are not yet certain of the reason for this. However, overexpression of p16 is not limited to CRC, but is also seen in other gastrointestinal tumors, such as gastric and intestinal cancers (24,25,30,50). Moreover, studies have shown that several human cancers display increased expression of negative cell cycle regulators, although no mutations of the p27<sup>Kip1</sup> and p21<sup>Waf1</sup> genes have been reported for human cancer tissues. High levels of p21<sup>Waf1</sup> expression are seen in glial tumors, non-small cell lung cancer, and breast cancer (51-53). p27<sup>Kip1</sup> expression is increased in a subset of cancers, including breast and colon cancers (29,54). The precise reason for why negative regulators of the cell cycle often display increased expression is unknown at present. One explanation proposed by Weinstein

is that multistage carcinogenesis is not simply a summation of the individual effects of oncogene activation and tumor suppressor gene inactivation, but that the evolving cancer cell must maintain a state of homeostasis between positive- and negative-acting factors in order to maintain structural integrity, viability, and normal replication (55). In this context, we speculate that p16 gene methylation may break the homeostatic balance, thereby tipping the balance towards positive regulators.

In conclusion, our study demonstrated that CRC tissues exhibited a variable methylation density of the CpG island in the p16 gene promoter, suggesting that p16 expression may be repressed in a methylation-dependent manner. Our data suggest that the majority of CRC tissues overexpressed p16 protein, and that low p16 expression among CRC tissues, probably via hypermethylation, may contribute to tumor enlargement and lymph node metastasis.

### Acknowledgements

This study was supported by a Grant-in-Aid for Cancer Research from the Ministry of Education, Science, Sports and Culture, Japan to H.Y.

### References

- Hunter T and Pines J: Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. *Cell* 79: 573-582, 1994.
- Sherr CJ: G1 phase progression: cycling on cue. *Cell* 79: 551-555, 1994.
- Kamb A, Gruis NA, Weaver FJ, Liu Q, Harshman K, Tavitgian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. *Science* 264: 436-440, 1994.
- Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. *Nature* 368: 753-756, 1992.
- Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* 366: 704-707, 1993.
- Jin X, Nguyen D, Zhang WW, Kyritsis AP and Roth JA: Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. *Cancer Res* 55: 3250-3253, 1995.
- Serrano M, Lee H, Chin L, Cordon-CC, Beach D and De Pinho RA: Role of the INK4a locus in tumor suppression and cell mortality. *Cell* 85: 27-37, 1996.
- Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M and Nakamura Y: Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. *Biochem Biophys Res Commun* 202: 1426-1430, 1994.
- Mori T, Miura K, Aoki T, Nishihira T, Mori S and Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. *Cancer Res* 54: 3396-3397, 1994.
- Schmidt EE, Ichimura K, Reifenger G and Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. *Cancer Res* 54: 6321-6324, 1994.
- Caldas C, Hahn SA, Da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat Genet* 8: 27-32, 1994.
- Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M and Uchida K: Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. *Cancer Res* 55: 2756-2760, 1995.

13. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res* 55: 4525-4530, 1995.
14. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. *Nat Med* 1: 686-692, 1995.
15. Tominaga O, Nita ME, Nagawa H, Fujii S, Tsuruo T and Muto T: Expressions of cell cycle regulators in human colorectal cancer cell lines. *Jpn J Cancer Res* 88: 855-860, 1997.
16. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R and Westra W: Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. *Nat Genet* 11: 210-212, 1995.
17. Ohhara M, Esumi M and Kurosu Y: Activation but not inactivation of the MTS1 gene is associated with primary colorectal carcinomas. *Biochem Biophys Res Commun* 226: 791-795, 1996.
18. Guan RJ, Fu Y, Holt PR and Pardee AB: Association of K-ras mutations with p16 methylation in human colon cancer. *Gastroenterology* 116: 1063-1071, 1999.
19. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT and Chaubert P: Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. *Lab Invest* 81: 217-229, 2001.
20. Yi J, Wang ZW, Cang H, Chen YY, Zhao R, Yu BM and Tang XM: p16 gene methylation in colorectal cancers associated with Duke's staging. *World J Gastroenterol* 7: 722-725, 2001.
21. Esteller M, Gonzalez S, Riscues RA, Marcuello E, Manguers R, Germa JR, Herman JG, Capella G and Peinado MA: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. *J Clin Oncol* 19: 299-304, 2001.
22. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Wu MS, Wang SM, Lin JT and Cheng AL: Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. *Oncology* 57: 149-156, 1999.
23. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M and Porschen R: Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. *Cancer Res* 58: 3942-3945, 1998.
24. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y and Enders GH: p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. *Gastroenterology* 119: 929-942, 2000.
25. Palmqvist R, Rutegard JN, Bozoky B, Landberg G and Stenling R: Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. *Am J Pathol* 157: 1947-1953, 2000.
26. Boyes J and Bird A: Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. *EMBO J* 11: 327-333, 1992.
27. Hsieh CL: Dependence of transcriptional repression on CpG methylation density. *Mol Cell Biol* 14: 5487-5494, 1994.
28. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N and Monden M: JTE-522, a cyclo-oxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. *Gastroenterology* 125: 556-571, 2003.
29. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H and Weinstein IB: Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. *Cancer Res* 58: 114-122, 1998.
30. Tsujie M, Yamamoto H, Tomita N, Sugita Y, Ohue M, Sakita I, Tamaki Y, Sekimoto M, Doki Y, Inoue M, Matsuura N, Monden T, Shiozaki H and Monden M: Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. *Oncology* 58: 126-136, 2000.
31. Geradts J, Kratzke RA, Niehans GA and Lincoln CE: Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/ multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. *Cancer Res* 55: 6006-6011, 1995.
32. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J and Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. *Cancer Res* 56: 3630-3633, 1996.
33. Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T, Takayama O, Fukunaga H, Miyake Y, Ikenaga M, Ikeda M, Sekimoto M, Matsuura N and Monden M: Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. *J Clin Oncol* 20: 4232-4241, 2002.
34. Ueda K, Miyoshi Y, Tokino T, Watatani M and Nakamura Y: Induction of apoptosis in T98G glioblastoma cells by transfection of GML, a p53 target gene. *Oncol Res* 11: 125-132, 1999.
35. Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, Matsumoto T, Aihara T, Tomita N, Tamaki Y, Sakita I, Kikkawa N, Matsuura N, Shiozaki H and Monden M: Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. *Cancer Res* 60: 3043-3050, 2000.
36. Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, Nagano H, Umeshita K, Sakon M, Matsuura N, Nakamori S and Monden M: Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. *Hepatology* 34: 638-650, 2001.
37. Miyake Y, Fujiwara Y, Ohue M, Yamamoto H, Sugita Y, Tomita N, Sekimoto M, Shiozaki H and Monden M: Quantification of micrometastases in lymph nodes of colorectal cancer using real-time fluorescence polymerase chain reaction. *Int J Oncol* 16: 289-293, 2000.
38. Lo YM, Wong IH, Zhang J, Tein MS, Ng MH and Hjelm NM: Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. *Cancer Res* 59: 3899-3903, 1999.
39. Polyak K, Hamilton SR, Vogelstein B and Kinzler KW: Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. *Am J Pathol* 149: 381-387, 1996.
40. Matsushita K, Kobayashi S, Kato M, Itoh Y, Okuyama K, Sakiyama S and Isono K: Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. *Int J Cancer* 69: 259-264, 1996.
41. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N and Ito H: Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. *Cancer* 79: 2067-2072, 1997.
42. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava PI, Kapusta L, Franssen E, Pritchard KI and Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. *Nat Med* 3: 227-230, 1997.
43. Bender CM, Pao MM and Jones PA: Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. *Cancer Res* 58: 95-101, 1998.
44. Myohanen SK, Baylin SB and Herman JG: Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. *Cancer Res* 58: 591-593, 1998.
45. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M and Kitajima M: Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. *Clin Cancer Res* 3: 2229-2236, 1997.
46. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N and Monden M: Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. *Hepatology* 30: 90-99, 1999.
47. Lee CT, Capodice P, Osman I, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C: Overexpression of the cyclin-dependent kinase inhibitor p16 associated with tumor recurrence in human prostate cancer. *Clin Cancer Res* 5: 977-983, 1999.
48. Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, Hurst T, Khoo SK and Parsons PG: Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavorable prognosis. *Int J Cancer* 74: 57-63, 1997.

49. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G and Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. *Int J Cancer* 79: 71-75, 1998.
50. Arber N, Hibshoosh H, Yasui W, Neugut AI, Hibshoosh A, Yao Y, Sgambato A, Yamamoto H, Shapira I, Rosenman D, Fabian I, Weinstein IB, Tahara E and Holt PR: Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. *Cancer Epidemiol Biomarkers Prev* 8: 1101-1105, 1999.
51. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA and Zhang W: Increased levels of p21WAF1/Cip1 in human brain tumors. *Oncogene* 11: 2021-2028, 1995.
52. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, Chella A, Merlo G, Angeletti CA, Dalla PP and Bevilacqua G: p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. *Oncogene* 12: 1319-1324, 1996.
53. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, Dalla PP and Harris AL: p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. *Br J Cancer* 74: 208-215, 1996.
54. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ and Lu X: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. *Proc Natl Acad Sci USA* 94: 6380-6385, 1997.
55. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heel of cancer. *Science* 297: 63-64, 2002.

## Effects of p21<sup>cip1/waf1</sup> overexpression on growth, apoptosis and differentiation in human colon carcinoma cells

HIKARU IZAWA, HIROFUMI YAMAMOTO, BAZARRAGCHAA DAMDINSUREN, KIMIMASA IKEDA, MASAKI TSUJIE, REI SUZUKI, KOTARO KITANI, YOSUKE SEKI, TARO HAYASHI, ICHIRO TAKEMASA, MASATAKA IKEDA, MASAYUKI OHUE, MITSUGU SEKIMOTO, TAKUSHI MONDEN and MORITO MONDEN

Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan

Received December 28, 2004; Accepted February 18, 2005

**Abstract.** The cyclin-dependent kinase inhibitor p21<sup>cip1/waf1</sup> negatively regulates the progression of cell cycle and the potential usefulness of p21<sup>cip1/waf1</sup> gene is proposed in gene therapy. However, studies have demonstrated a protective role of p21<sup>cip1/waf1</sup> against apoptosis and little is known about effects of ectopic expression of p21<sup>cip1/waf1</sup> on differentiation of colon cancer cells. In the present study, we found diffuse p21<sup>cip1/waf1</sup> expression in only a few clinical samples of colorectal cancer with wild-type p53 gene. To explore the role of p21<sup>cip1/waf1</sup> in cell growth, apoptosis and differentiation, we constitutively overexpressed p21<sup>cip1/waf1</sup> in HT29 colon carcinoma cells. Ectopic overexpression of p21<sup>cip1/waf1</sup> was associated with inhibition of CDK2-associated kinase activity, indicating the functionality of the introduced p21<sup>cip1/waf1</sup> gene. Overexpression of p21<sup>cip1/waf1</sup> caused an appreciable growth inhibition in monolayer and soft agar cultures and it significantly reduced sodium butyrate- but not 5-fluorouracil-induced apoptosis. p21<sup>cip1/waf1</sup> overexpressing cells exhibited marked decrease of intestinal differentiation when assayed with intestinal alkaline phosphatase. Our findings suggest that introduction of p21<sup>cip1/waf1</sup> gene into colon cancer cells may be useful for inhibiting cell growth but caution should be taken regarding the increased resistance to certain apoptosis-inducing agents and dysregulation of endogenous p21<sup>cip1/waf1</sup>-mediated differentiation process.

### Introduction

Progression of cells through the cell cycle is under positive control by a series of specific cyclin/cyclin-dependent kinase (CDK) complexes and it is negatively controlled by specific

CDK inhibitors (1). The latter includes the Cip/Kip family, which consists of several members such as p21<sup>cip1/waf1</sup> (designated p21 hereafter), p27<sup>kip1</sup> and p57<sup>kip2</sup>. These proteins share a conserved N-terminal domain and inhibit a broad range of CDKs by binding to several cyclin/CDK complexes, including cyclin D/CDK4 (or CDK6), cyclin E/CDK2 and cyclin A/CDK2.

The expression of p21 gene is regulated through either p53-dependent or -independent pathway (2). The p21 protein can inhibit CDK/cyclin activities and overexpression of p21 causes G1 arrest (3). p21 also physically interacts with proliferative cell nuclear antigen (PCNA) and blocks DNA replication (3). Therefore, p21 is a strong negative regulator of cell proliferation. Dysregulation of the cell cycle components including p21 has been shown in many types of human cancer. Accumulating evidence indicates low levels of p21 in colonic dysplastic aberrant crypt foci and carcinoma of the colon (4,5), although mutation of p21 gene is very rare in human cancers (6). Based on these findings, it was proposed that ectopic overexpression of p21 might be useful in the treatment of colon cancer (5,7). At present, gene therapy utilizing a wild-type p53, an inducer of p21, is being tested in various human cancers. However, the significance of p21 molecule in gene therapy is not fully determined.

p21 was reported to promote as well as inhibit apoptosis (8-12), and to have no effect on this process (13,14). Thus, the exact role of p21 in apoptosis remains controversial. p21 is also involved in the process of cell differentiation. *In vitro*, p21 is coupled to differentiate in myocytes, hepatoma, hematopoietic and neuroblastoma cells by various types of differentiation inducers [including phorbol ester, vitamin D3, tumor necrosis factor (TNF)- $\alpha$ , MyoD and nerve growth factor plus aphidicolin] (15-19). In gut differentiation, p21 level increases during the differentiation of Caco-2 colon carcinoma cells (20,21), and sodium butyrate, an inducer of differentiation, up-regulates p21 in HT29 colon carcinoma cells (22). Considering the dynamic change of p21 in the differentiation processes, ectopic expression of p21 appears to exert a favorable effect, i.e., enhancement of cell differentiation.

The overall theme of the present study was to evaluate the efficacy of p21 gene therapy. Specifically, we examined p21 expression in clinical samples of multistage carcinogenesis of the colorectum. Based on the observation that abundant p21 expression was noted only in a few clinical samples of colo-

---

*Correspondence to:* Dr Hirofumi Yamamoto, Department of Surgery and Clinical Oncology (E2), Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita city, Osaka 565-0871, Japan

E-mail: kobunyam@surg2.med.osaka-u.ac.jp

**Key words:** colorectal cancer, adenomatous polyps, p53, p21, apoptosis, cell growth, differentiation, gene therapy

rectal cancer (CRC) with wild-type of *p53* gene, we introduced *p21* cDNA into *p53* mutant HT29 colon cancer cells and examined its diverse effects on cell growth, apoptosis and cell differentiation.

### Materials and methods

**Cell lines and tissues.** The HCT116, SW480 and HT29 human colon carcinoma cell lines were obtained from the American Type Culture Collection (Manassas, VA). The HCT116 cell line was grown in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin in 5% CO<sub>2</sub> at 37°C. We also used 53 colorectal carcinomas and paired adjacent normal mucosa samples, 40 samples of adenomatous colorectal polyps (30 tubular and 10 tubulo-villous adenomas) and 19 polyps containing focal carcinomas. All human samples were collected during surgery or during endoscopic polypectomy in our department. The samples were fixed in buffered formalin at 4°C overnight and embedded in paraffin. For Western blot analyses, a piece of tissue was immediately frozen in liquid nitrogen and stored at -80°C.

**Immunostaining.** For immunocytostaining, the cells were fixed on the slide in 10% buffered formalin for 10 min. Immunostaining was performed by an avidin-biotin complex method. Anti-human p21 monoclonal antibody (mAb, Oncogene Research Products, Calbiochem, San Diego, CA) and anti-p53 mAb (Novocastra, Newcastle, UK) were applied to the sections at a dilution of 1:50 for both. A negative control section, to which normal mouse serum had been applied, was included in each staining procedure.

**Mutation analysis.** For detection of mutations in *p53* gene, the polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) analysis was employed. First, exons 5-8 of the *p53* gene were amplified by PCR using the primers described previously (23). Then, 1.5 µl of 1/10 (v/v) of PCR-amplified products were added to 1.5 µl of a mixture of deoxynucleotide triphosphate (60 µM), <sup>32</sup>P-end-labeled primers (0.1 µM each), MgCl<sub>2</sub> (1.5 mM), Tris-HCl (pH 8.3, 10 mM), KCl (50 mM) and 0.1 units of Tag polymerase. PCR amplification was then performed for 20 cycles. The annealing temperatures were 60, 64, 62 and 62°C for exons 5, 6, 7 and 8, respectively. The SSCP analysis was performed with the following modifications. Briefly, the PCR product (3 µl) was diluted 10-fold with stop solution [20 mM ethylenediaminetetraacetic acid (EDTA), 95% formamide, 0.05% bromophenol blue and 0.05% xylene cyanol] and heat-denatured at 98°C for 5 min. One µl of this mixture was loaded onto an 8% non-denaturing acrylamide gel (acrylamide:methylenebis-acrylamide, 80:1) and run at a constant voltage of 400 V at room temperature for 12-16 h. The gel was then vacuum-dried and exposed to Kodak X-OMAT film at room temperature for 1-2 days.

**Flow cytometric analysis.** The cells were trypsinized, collected and washed twice with PBS, and then flow cytometric analysis was performed. Briefly, after fixation in 70% cold ethanol, the cell pellets were resuspended in 400 µl of 0.2 mg/ml

propidium iodide (PI) containing 0.6% Nonidet P-40 (NP-40) plus the same volume of 1 mg/ml RNase (Sigma, St. Louis, MO) and then incubated in the dark at room temperature for 30 min. The cell suspension was then filtered through a 60 µm Spectra mesh filter and analyzed with a flow cytometer. The percentage of cells in different phases of the cell cycle was determined with a ModFit 5.2 software.

**Apoptosis.** For the detection of apoptotic cells, both adherent and floating cells were pooled, fixed in 10% buffered formalin and stained with DAPI (4',6-diamidino-2-phenylindole, Boehringer Mannheim, Indianapolis, IN) solution on the glass slides. The cells were incubated with DAPI solution at a concentration of 1.5 µg/ml in PBS for 30 min and then washed in PBS for 2 h. For quantitation of apoptotic cells, 10 microscopic fields were randomly chosen at x25 magnification, and pictures were taken under light (for whole cells) or fluorescence (for DAPI-positive cells) microscopy. The total number of the cells and the number of apoptotic cells (those with nuclear fragmentation or condensation) were counted in each field. Over 700 total cells were counted in each sample, and the percentage of the apoptotic cells was calculated. The examiner who counted the number of apoptotic cells was blinded to the histopathological diagnosis in the case of human tissues.

**Western blot analysis.** The cell pellets were resuspended in lysis buffer [50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml aprotinin and 10 µg/ml leupeptin] and the lysates were clarified by centrifugation at 15,000 x g for 5 min at 4°C. Total cellular protein was determined with Bradford protein assay (Bio-Rad, Hercules, CA). The protein samples (100 µg) were subjected to SDS-polyacrylamide gel electrophoresis as described previously (24). The mouse mAb to p21 and rabbit polyclonal antibody to actin (Sigma) were used at the concentrations recommended by the manufacturers.

**Monolayer cell growth curves.** The cells were plated in triplicate at a density of 2x10<sup>4</sup> per well in 35-mm well dishes with 3 ml of DMEM medium plus 10% FBS. Cells were re-fed with fresh medium every 2 days. The number of cells was counted every 2 days for the subsequent days.

**Soft agar assay.** Assays for growth in 0.33% Noble agar (Difco Laboratories, Detroit, MI) were performed. In brief, 5x10<sup>4</sup> cells were suspended in DMEM with 10% FBS, containing 0.33% agar, and plated in triplicate in 35-mm well plates. After 2 weeks, the number colonies with a diameter of >2 mm were counted by microscopy.

**Assays for induction of alkaline phosphatase activity.** Intestinal alkaline phosphatase (Sigma) is a well-established marker of differentiation in HT29 cells and other colon cancer cell lines (22,25). Sodium butyrate (Sigma), a short-chain fatty acid, induces the differentiation of various cell types (22). Cells were seeded in duplicate at a density of 5x10<sup>4</sup> per well in 24-well plates in complete medium containing 10% FBS. Two days later, the cells were re-fed with 1 ml of fresh medium containing sodium butyrate at a concentration of 5 mM, and the cells were grown for an additional 3 days. Briefly, the cells




Figure 1. Western blot analysis for detection of p21 protein. Two cell lines, HCT116 (p53 wild-type) and SW480 (p53 mutant), and three colorectal carcinomas (T) and paired adjacent normal mucosa (N) samples were blotted using anti-p21 antibody.

were washed twice with PBS, fixed with citrate buffered acetone for 30 sec and then incubated with an alkaline dye mixture (fast violet B salt capsule, 2 ml of naphthol AS-MX phosphatase alkaline solution and 48 ml of distilled water) for 30 min, in the dark at room temperature. After washing with water, the cells were overlaid with PBS.

*In vitro assay for cyclin E, CDK2-associated kinase activity.*  
*In vitro* CDK2-associated kinase assays were performed as described previously (26), with minor modifications. After releasing from serum starvation, re-feeding with 10% FBS,

the cells were collected at 6 and 12 h and sonicated in kinase buffer (in lysis buffer described above plus 10 mM  $\beta$ -glycerophosphate, 1 mM NaF and 0.1 mM sodium orthovanadate). After centrifugation, the supernatant fraction was collected. Immunoprecipitation with 1  $\mu$ g of the CDK2 polyclonal antibody was carried out as described above and the beads were washed four times with kinase buffer, twice with reaction buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, 10 mM  $MgCl_2$ , 1 mM dithiothreitol (DTT), 2.5 mM ethylene glycol bis ( $\beta$ -aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 10 mM  $\beta$ -glycerophosphate, 1 mM NaF and 0.1 mM sodium orthovanadate]. The final pellets were resuspended in 45  $\mu$ l of reaction buffer containing 2  $\mu$ g of Histone H1 (Sigma) and 5  $\mu$ Ci of  $\gamma$ - $^{32}P$ -ATP, and incubated for 30 min at 30°C. The reaction mixture was then subjected to SDS-PAGE, and the intensity of phosphorylation of the Histone H1 substrate was determined by autoradiography.

*Statistical analysis.* All data were expressed as mean  $\pm$  SD. Differences between groups were examined for statistical significance by the Mann-Whitney test using the StatView




Figure 2. Immunostaining for p21 and p53. Expression of p21 and p53 in cell lines (A-D) and colorectal carcinomas (E-H). Nuclear staining for p21 was observed in HCT116 cells (A) and T1 tumor tissue (E), but not in SW480 cells (C), T2 (G) or T3 tumors (data not shown). Weak nuclear p53 was found in a small cell fraction of HCT116 (B), but strong staining was generally noted in SW480 (D). T1 tumor did not express p53 protein (F), while T2 tumor expressed the protein (H). When mouse non-immunized IgG was applied instead of primary antibody, no staining was obtained.

Table I. p21 expression in multistage carcinogenesis.

	Diffuse	Focal	Scarce	Negative
Adenomatous polyp (n=40)	0	0	12	28
Focal carcinoma in adenomatous polyp (n=19)	2	0	8	9
Advanced colorectal cancer (n=53)	3	3	6	41

J-5.0 program (SAS Institute Inc., Cary, NC). A p-value <0.05 denoted the presence of a statistically significant difference.

## Results

**Western blot analysis and immunostaining.** Western blot analysis was performed using anti-p21 antibody. The p21 protein was detected in p53 wild-type HCT116 cells, whereas p21 expression was only negligible in p53 mutant type SW480 cell line (Fig. 1). In three paired non-tumor and tumor tissues, only little p21 expression was noted except for one tumor tissue (T1). Nuclear p21 expression was observed in HCT116 cells (Fig. 2A) and T1 tumor tissue (Fig. 2E), but not in SW480 cells (Fig. 2C), T2 tumor tissue (Fig. 2G) or T3 tumor tissue (data not shown). When mouse non-immunized IgG was applied instead of the primary antibody, no staining was obtained. These findings indicate that the antibody specifically reacted with the p21 protein.

**Expression of p21 in polyps and cancer tissues.** p21 was expressed in the top part of the normal epithelium. Of 40 adenomatous polyps 12 samples occasionally displayed p21 expression in cells at the surface area of the polyps. In 19 focal carcinoma in adenomatous polyps, diffuse p21 expression was identified in 2 focal carcinomas and only a small number of cancer cells expressed p21 in 8 focal carcinomas. Of 53 advanced colorectal cancers, diffuse p21 expression was found in 3 cases, and focal expression (in 3 cases) or only an occasional expression (in 6 cases) was noted. These results are summarized in Table I.

**Relationship between p21 and p53 expression and mutation status.** Since it is postulated that p53 is one of the inducers of p21 expression, we examined p53 expression in colon cancer cell lines and in a series of samples. A weak nuclear p53 expression was found in HCT116, but strong staining was generally noted in SW480 (Fig. 2B and D). Immunoreactivity for p53 was not observed in adenomatous polyps. T1 tumor did not express p53 protein, while T2 tumor expressed the protein (Fig. 2F and H). The relationship between p53 and p21 expression in focal carcinoma and advanced colorectal cancer tissue is shown in Table II, and no significant correlation was found. No p53 gene mutations were detected in three advanced cancers with diffuse p21 expression (Fig. 3A-C). On the

Table II. Relationship between p53 and p21 expression in focal carcinoma in adenomatous polyps and advanced colorectal cancers.

	p53	
Focal carcinoma in adenomatous polyp (n=19)	+	
p21		
+	5	5 (2) <sup>a</sup>
-	6	3
Advanced colorectal cancer (n=53)		
p21		
+	1	11 (3) <sup>a</sup>
-	28	13

<sup>a</sup>Diffuse expression.

other hand, mutation of p53 gene in exon 7 was detected in the T2 tumor (p21-negative) (Fig. 3D).

**Inhibition of CDK2 kinase in p21-overexpressing clones.** Western blot analysis identified two clones that overexpressed p21 protein (#C1, #C2), compared with two vector control derivatives, Vp (a pool of vector control clones) and V1 (a single vector control clone) (Fig. 4A). Equal protein loading of each lane was confirmed by the blot for actin. *In vitro* CDK2-associated kinase assay indicated that the two p21-overexpressing clones displayed reduced kinase activity compared with the control cells (Fig. 4B). These results indicated that the overexpressed p21 protein was functional. Negative control studies showed that the use of non-immune rabbit serum for the immunoprecipitation resulted in negligible activities in the CDK2-kinase assays.

**Growth properties of p21-overexpressing HT29 derivatives.** In the next step, we generated growth curves using the two p21-overexpressing HT29 derivatives. Comparison with the vector control cells showed slow growth of the p21-overexpressers (Fig. 5). Cell cycle analyses showed increased G0/G1 population in p21 derivatives compared with the three control cells (Table III, p=0.002). When grown in agar in complete medium containing 10% FBS, the two control cell lines showed a colony forming efficiency of 26.7 and 27.0%, respectively. In contrast, the p21-overexpressing clones showed a decrease in colony forming efficiencies of 16.0 and 17.0%. These differences between two cell types were significant (p=0.031) and were also seen in two additional experiments.

**Differentiation of p21-overexpressing HT29 derivatives.** Histochemical analysis showed that alkaline phosphatase-positive cells were only rarely detected in the vector control cells and the p21-overexpressers. After induction of intestinal






Figure 3. Mutation analysis. The PCR-SSCP analysis was employed for the detection of *p53* gene mutations. No *p53* gene mutations were found in 3 advanced cancers that displayed a diffuse p21 expression (A-C). However, T2 tumor (p21-negative) had *p53* gene mutation in exon 7 (D).




Figure 4. Inhibition of CDK2 kinase in p21 overexpressing cells. (A), We identified two clones that overexpressed p21 protein (#C1, #C2), compared with two vector control derivatives, Vp (a pool of vector control clones) and V1 (a single vector control clone). Equal protein loading of each lane was confirmed by the blot for actin. (B), *In vitro* CDK2-associated kinase assay indicated that the two p21-overexpressing clones displayed low kinase activity compared with the control cells.




Figure 5. Growth properties of HT29 derivatives overexpressing p21. Using the two HT29 derivatives that overexpress p21, growth curves were drawn over eight days. Note the apparent slow growth of p21 overexpressers compared with the vector control cells.

differentiation, the subconfluent cultures of control cells displayed abundant alkaline phosphatase-positive cells, whereas the subconfluent cultures of the p21 overexpressers showed only a faint alkaline phosphatase expression (Fig. 6).

**Effects of p21 on sodium butyrate-induced apoptosis.** Since sodium butyrate is also a well-known apoptosis-inducing agent in various cell culture systems (27), we examined the effects of p21 on sodium butyrate-induced apoptosis. Sodium butyrate at 5 mM induced marked apoptosis in two vector control cell lines ( $26.5 \pm 2.2\%$  and  $26.0 \pm 1.3\%$  of total cells, respectively). On the other hand, p21 overexpressers induced a milder degree of apoptosis ( $15.2 \pm 1.6\%$  and  $18.3 \pm 1.7\%$ ,

Table III. Cell cycle distribution of p21 derivatives.

Cell type	Vp	V1	V2	#C1	#C2
Cell cycle distribution (%)					
G0/G1 <sup>a</sup>	54.7	53.4	54.0	66.0	63.6
S	31.4	32.5	31.9	24.2	25.9
G2/M	13.8	14.1	14.1	9.8	10.5

<sup>a</sup>Values were significantly higher in p21 derivatives #C1 and #C2 when compared to the control cells ( $p=0.002$ ).




Figure 6. Differentiation of p21-overexpressing HT29 derivatives. Histochemical analyses showed that alkaline phosphatase-positive cells were rarely detected in the vector control cells and p21 overexpressers. After induction of intestinal differentiation, the subconfluent cultures of control cells displayed intense and frequent alkaline phosphatase-positive cells, whereas subconfluent cultures of the p21 overexpressers showed a faint alkaline phosphatase expression.




Figure 7. Effects of p21 on sodium butyrate-induced apoptosis. Apoptosis induced by 5 mM sodium butyrate was significantly more evident in the two vector control cell lines than the p21 overexpressers. Data are mean  $\pm$  SD of three independent experiments. \* $p < 0.05$  by the Mann-Whitney test.

respectively) (Fig. 7). The difference between the vector pool and p21 derivatives was significant ( $p < 0.05$  for both). When 5-FU was used at  $IC_{50}$ , no difference in apoptotic cells was found between p21 overexpressers and the control cells (data not shown).

## Discussion

In the present study, we found high p21 expression in a subset of CRC and a generally low p21 level in the majority of CRC. Especially, diffuse expression of p21 was noted only

in CRC with wild-type *p53* gene (7,28). Several studies showed a higher p21 expression in CRC compared to that of the present study. The different results may be due to differences in the antibody used or the criterion used for positivity (i.e., cut-off point), but at least our data indicate that p21 is not up-regulated during adenoma carcinoma sequence and that p21 is unlikely to be expressed abundantly in CRC tissues.

Using clinical samples, previous studies reported that p21 expression is associated with better prognosis in several types of human malignancies including carcinomas of the stomach and pancreas (29,30). Considering the known role of p21 in regulation of proliferation based on CDK inhibitory function as well as suppression of PCNA, the strategy of *p21* gene transduction appears to be reasonable. In particular, CRC with mutant *p53* gene may be an appropriate candidate and this category is estimated at approximately 50% CRC (31). Indeed, ectopic expression of p21 seems to be functional even in malignant cells because it inhibits growth and tumorigenicity in human brain tumor cells, prostate cancer cells, HeLa cervical carcinoma cells and rat glioma cells (32-35). In the present study, we constitutively overexpressed p21 in *p53*-mutant HT29 colon carcinoma cells and found that p21 overexpressing cells grew slower in monolayer cultures. Growth suppression in 3-D soft agar cultures was also evident. Since the latter assay is thought to reflect *in vivo* growth, the effect of growth suppression is promising. However, previous studies showed that p21 is involved not only in cell growth, but also in other aspects of cellular process including apoptosis and cellular differentiation (as mentioned in Introduction).

Several studies showed the coupling of marked up-regulation of endogenous p21 with apoptosis in various cell types in response to certain agents including taxol, okadaic acid, etoposide, IFN- $\gamma$  (36-39), suggesting that p21 may be a crucial factor that modulates cell viability. In the present study, we found that overexpression of p21 inhibited sodium butyrate-induced apoptosis rather than enhanced it. This finding is consistent with the cumulative evidence on the protective role of p21 in apoptosis. Cyclopentenone prostaglandin A2 (PGA2)-mediated cell death is promoted by antisense p21 in MCF-7 breast cancer cells and it is diminished by ectopic expression of p21 in RKO colon carcinoma cells (12,40). The loss of p21 sensitizes the HCT116 colon carcinoma cells to killing by UV-irradiation,  $\gamma$ -irradiation, cisplatin and nitrogen mustard (41,42). On the other hand, induction of p21 with an inducible expression system did not affect adriamycin-induced apoptosis of DLD1 colon carcinoma cells (43) and p21 antisense resulted in equal sensitivity to AraC-induced apoptosis of HL60 (44), being consistent with our results of 5-FU treatment. Furthermore, overexpression of p21 led to increased sensitivity to doxorubicin and methotrexate in an osteosarcoma cell line (9) and enhanced radiosensitivity in rat glioma cells (10). Taken together, it is possible that p21 can act as either a reducer or enhancer of apoptosis depending on the type of agents used and cell types.

p21 is thought to play a role in differentiation in several leukemia cells and tumor cells (18,32). In normal epithelia of various organs, p21 expression is associated with terminal differentiation (20). p21 plays a role in differentiation in leukemia cells, neuroblastoma cells and mice keratinocytes

(14,16-18). Thus antisense to p21 decreased monocytic differentiation of HL60 (44) and p21-deficient keratinocytes underwent down-modulated differentiation (45). Conversely, there is direct evidence that overexpression of p21 induces differentiation in the myelomonocytic cell line and megakaryoblastic leukemia cell line (46,47). These findings strongly suggest that p21 is an indispensable molecule acting during differentiation of cells of various origins. However, Di Cunto *et al* (48) surprisingly demonstrated that overexpression of p21 blocked the differentiation of keratinocytes. In our study, we found that p21 overexpression inhibited intestinal cell differentiation. Taken together, ectopic overexpression of p21 may not always enhance cellular differentiation, rather it can perturb the normal process of cellular differentiation in certain conditions.

There is no doubt, based on numerous studies, that p21 can inhibit cell growth. Therefore, p21 is one of the appropriate choices against human carcinomas such as hepatocellular carcinoma, in which cell proliferation positively correlates with prognosis (49), or pancreatic carcinoma, which progress rapidly. However, it is possible that the unfavorable outcome might be produced with regard to differentiation and apoptosis, depending on the cancer cell type. Thus, the diverse effects of forced expression of p21, especially the influence on chemotherapy, should be carefully evaluated in the application of p21 molecule in human gene therapy.

## References

- Hunter T and Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. *Cell* 79: 573-582, 1994.
- Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation and DNA damage. *Genes Dev* 9: 935-944, 1995.
- Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev* 9: 1149-1163, 1995.
- Polyak K, Hamilton SR, Vogelstein B and Kinzler KW: Early alterations of cell-cycle-regulated gene expression in colorectal neoplasia. *Am J Pathol* 149: 381-387, 1996.
- Dogliani C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F and Barbareschi M: p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. *J Pathol* 179: 248-253, 1996.
- Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B and Koeffler HP: Absence of WAF1 mutations in a variety of human malignancies. *Blood* 84: 3781-3784, 1994.
- Matsushita K, Kobayashi S, Kato M, Itoh Y, Okuyama K, Sakiyama S and Isono K: Reduced messenger RNA expression level of p21CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. *Int J Cancer* 69: 259-264, 1996.
- Sheikh MS, Rochefort H and Garcia M: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. *Oncogene* 11: 1899-1905, 1995.
- Li WW, Fan JG, Hochhauser D and Bertino JR: Overexpression of p21(waf1) leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. *Cancer Res* 57: 2193-2199, 1997.
- Hsiao M, Tse V, Carmel J, Costanzi E, Strauss B, Haas M and Silverberg GD: Functional expression of human p21(WAF1/CIP1) gene in rat glioma cells suppresses tumor growth *in vivo* and induces radiosensitivity. *Biochem Biophys Res Commun* 233: 329-335, 1997.
- Wang J and Walsh K: Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. *Science* 273: 359-361, 1996.
- Gorospe M, Wang X, Guyton KZ and Holbrook NJ: Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. *Mol Cell Biol* 16: 6654-6660, 1996.
- Attardi LD, Lowe SW, Brugarolas J and Jacks T: Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. *EMBO J* 15: 3693-3701, 1996.
- Kobayashi T, Consoli U, Andreeff M, Shiku H, Deisseroth AB and Zhang W: Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. *Oncogene* 11: 2311-2316, 1995.
- Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA and El-Houseini ME: Induction of p21 (WAF-1/CIP1) during differentiation. *Oncogene* 9: 3389-3396, 1994.
- Guo K, Wang J, Andres V, Smith RC and Walsh K: MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. *Mol Cell Biol* 15: 3823-3829, 1995.
- Schwaller J, Koeffler HP, Niklaus G, Loetscher P, Nagel S, Fey MF and Tobler A: Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SD11 in differentiating human leukemic cells. *J Clin Invest* 95: 973-979, 1995.
- Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL and Ross AH: The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. *Mol Cell Biol* 16: 1335-1341, 1996.
- Yoshida K, Murohashi I and Hirashima K: p53-independent induction of p21(WAF1/CIP1) during differentiation of HL-60 cells by tumor necrosis factor alpha. *Int J Hematol* 65: 41-48, 1996.
- Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, El-Deiry WS and Tyner AL: p21 (WAF1/CIP1) expression is induced in newly non-dividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. *Exp Cell Res* 227: 171-181, 1996.
- Evers BM, Ko TC, Li J and Thompson EA: Cell cycle protein suppression and p21 induction in differentiating Caco-2 cells. *Am J Physiol* 271: G722-G777, 1996.
- Siavoshian S, Blottiere HM, Cherbut C and Galmiche JP: Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase 2 expression in HT29 colonic epithelial cells. *Biochem Biophys Res Commun* 232: 169-172, 1997.
- Ohue M, Tomita N, Monden T, *et al*: A frequent alteration of p53 gene in carcinoma in adenoma of colon. *Cancer Res* 54: 4798-4804, 1994.
- Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damsduren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N and Monden M: JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. *Gastroenterology* 125: 556-571, 2003.
- Basson MD, Turowski GA, Rashid Z, Hong F and Madri JA: Regulation of human colonic cell line proliferation and phenotype by sodium butyrate. *Dig Dis Sci* 41: 1989-1993, 1996.
- Doki Y, Imoto M, Han EK, Sgambato A and Weinstein IB: Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1. *Carcinogenesis* 18: 1139-1148, 1997.
- Hague A, Elder DJ, Hicks DJ and Paraskeva C: Apoptosis in colorectal tumor cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. *Int J Cancer* 60: 400-406, 1995.
- Yasui W, Akama Y, Yokozaki H, Semba S, Kudo Y, Shimamoto F and Tahara E: Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. *Pathol Int* 47: 470-477, 1997.
- Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N and Ito H: Expression of p21 (waf1/cip1/sd11), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. *Cancer* 79: 2067-2072, 1997.
- Dergham ST, Dugan MC, Joshi US, Chen YC, Du W, Smith DW, Arlauskas P, Crissman JD, Vaitkevicius VK and Sarkar FH: The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma. *Cancer* 80: 372-381, 1997.
- Galizia G, Lieto E, Ferraraccio F, Orditura M, De Vita F, Castellano P, Imperatore V, Romano C, Ciardiello F, Agostini B and Pignatelli C: Determination of molecular marker expression can predict clinical outcome in colon carcinomas. *Clin Cancer Res* 10: 3490-3499, 2004.

32. Yang ZY, Perkins ND, Ohno T, Nabel EG and Nabel GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity *in vivo*. *Nat Med* 1: 1052-1056, 1995.
33. Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y and Nisen PD: Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. *Oncogene* 13: 1395-1403, 1996.
34. Eastham JA, Hall SJ, Sehgal I, *et al*: *In vivo* gene therapy with p53 or p21 adenovirus for prostate cancer. *Cancer Res* 55: 5151-5155, 1995.
35. Yokoyama Y, Takahashi Y, Morishita S, Hashimoto M and Tamaya T: Introduction of p21(Waf1/Cip1) gene into a carcinoma cell line of the uterine cervix with inactivated p53. *Cancer Lett* 116: 233-239, 1997.
36. Kano A, Watanabe Y, Takeda N, Aizawa S and Akaike T: Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. *J Biochem (Tokyo)* 121: 677-683, 1997.
37. Torres K and Horwitz SB: Mechanisms of Taxol-induced cell death are concentration dependent. *Cancer Res* 58: 3620-3626, 1998.
38. Sheikh MS, Garcia M, Zhan Q, Liu Y and Fornace AJ Jr: Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. *Cell Growth Differ* 7: 1599-1607, 1996.
39. Chen G, Shu J and Stacey DW: Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide. *Oncogene* 15: 1643-1651, 1997.
40. Gorospe M, Liu Y, Xu Q, Chrest FJ and Holbrook NJ: Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. *Mol Cell Biol* 16: 762-770, 1996.
41. McDonald ER III, Wu GS, Waldman T and El-Deiry WS: Repair defect in p21 WAF1/CIP1 *-/-* human cancer cells. *Cancer Res* 56: 2250-2255, 1996.
42. Waldman T, Lengauer C, Kinzler KW and Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. *Nature* 381: 713-716, 1996.
43. Sheikh MS, Chen YQ, Smith ML and Fornace AJ Jr: Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. *Oncogene* 14: 1875-1882, 1997.
44. Freereman AJ, Vrana JA, Tombes RM, Jiang H, Chellappan SP, Fisher PB and Grant S: Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). *Leukemia* 11: 504-513, 1997.
45. Missero C, Di Cunto F, Kiyokawa H, Koff A and Dotto GP: The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. *Genes Dev* 10: 3065-3075, 1996.
46. Liu M, Lee MH, Cohen M, Bommakanti M and Freedman LP: Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. *Genes Dev* 10: 142-153, 1996.
47. Matsumura I, Ishikawa J, Nakajima K, Oritani K, Tomiyama Y, Miyagawa J, Kato T, Miyazaki H, Matsuzawa Y and Kanakura Y: Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5. *Mol Cell Biol* 17: 2933-2943, 1997.
48. Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth PK and Dotto GP: Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. *Science* 280: 1069-1072, 1998.
49. King KL, Hwang JJ, Chau GY, Tsay SH, Chi CW, Lee TG, Wu LH, Wu CW and Lui WY: Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. *J Gastroenterol Hepatol* 13: 273-279, 1998.

## Genetic Polymorphism in Cytochrome P450 7A1 and Risk of Colorectal Cancer: The Fukuoka Colorectal Cancer Study

Tomoko Hagiwara,<sup>1</sup> Suminori Kono,<sup>1</sup> Guang Yin,<sup>1</sup> Kengo Toyomura,<sup>1</sup> Jun Nagano,<sup>1</sup> Tetsuya Mizoue,<sup>1</sup> Ryuichi Mibu,<sup>2</sup> Masao Tanaka,<sup>2</sup> Yoshihiro Kakeji,<sup>3</sup> Yoshihiko Maehara,<sup>3</sup> Takeshi Okamura,<sup>4</sup> Kouji Ikejiri,<sup>5</sup> Kitaroh Futami,<sup>6</sup> Youichi Yasunami,<sup>7</sup> Takafumi Maekawa,<sup>8</sup> Kenji Takenaka,<sup>9</sup> Hitoshi Ichimiya,<sup>10</sup> and Nobutoshi Imaizumi<sup>11</sup>

Departments of <sup>1</sup>Preventive Medicine, <sup>2</sup>Surgery and Oncology, and <sup>3</sup>Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka; <sup>4</sup>Department of Gastroenterological Surgery, National Kyushu Cancer Center, Notame, Minami-ku, Fukuoka; <sup>5</sup>Division of Surgery, National Kyushu Medical Center, Jigyohama, Chuo-ku, Fukuoka; <sup>6</sup>Department of Surgery, Fukuoka University Chikushi Hospital, Oaza-zokumyojin, Chikushimo-shi; <sup>7</sup>The First and <sup>8</sup>Second Departments of Surgery, Fukuoka University School of Medicine, Nanakuma, Jonan-ku, Fukuoka; <sup>9</sup>Division of Surgery, Fukuoka City Hospital, Yoshizuka-honmachi, Hakata-ku, Fukuoka; <sup>10</sup>Division of Surgery, Hamanomachi General Hospital, Maizuru, Chuo-ku, Fukuoka; and <sup>11</sup>Division of Surgery, Fukuoka Red Cross Hospital, Ogusu, Minami-ku, Fukuoka, Japan

### Abstract

Bile acids have long been implicated in the etiology of colorectal cancer, but epidemiologic evidence remains elusive. Cholesterol 7 $\alpha$ -hydroxylase (*CYP7A1*) is the rate-limiting enzyme in the synthesis of bile acids from cholesterol in the liver, and thus may be an important determinant of bile acid production. We examined the association between the *CYP7A1 A-203C* polymorphism and colorectal cancer. The *CYP7A1 A-203C* polymorphism was determined by the PCR-RFLP method in 685 incident cases of colorectal cancer and 778 controls randomly selected from a community in the Fukuoka area, Japan. The *CC* genotype was slightly less frequent in the case group, and the adjusted odds ratio for the *CC* versus *AA* genotype was 0.88 (95% confidence interval, 0.65-1.20). In the analysis by subsite of the colorectum, a decreased risk associated with the *CYP7A1 CC* genotype was observed for proximal colon cancer, but not for either distal colon or rectal cancer. The adjusted odds ratios (95% confidence intervals) of proximal colon cancer for the *CC* genotype were 0.63 (0.36-1.10) compared with the *AA* genotype, and 0.59 (0.37-0.96) compared with the *AA* and *AC* genotypes combined. A decreased risk of proximal colon cancer in relation to the *CC* genotype of *CYP7A1 A-203C*, which probably renders less activity of the enzyme converting cholesterol to bile acids, is new evidence for the role of bile acids in colorectal carcinogenesis. (Cancer Res 2005; 65(7): 2979-82)

### Introduction

Colorectal cancer is one of the most common cancers in the world, accounting for nearly 10% of all incident cases of cancer (1). Japan has experienced a rapid increase in mortality from colorectal cancer in the past 50 years (2), and is currently among the countries with the highest incidence rates worldwide (3). Bile acids have long been implicated in the etiology of colorectal cancer. Primary bile acids such as cholic and chenodeoxycholic acids are excreted in the liver, and are degraded to secondary bile acids,

mainly deoxycholic and lithocholic acids, by bacteria in the intestinal lumen. Animal studies showed that secondary bile acids promoted chemically induced colorectal cancer (4, 5), and recent *in vitro* studies have identified several molecular mechanisms of deoxycholic acid promoting colorectal carcinogenesis (6, 7).

Despite these experimental observations, epidemiologic evidence remains elusive regarding the role of bile acids in colorectal carcinogenesis. Fecal levels of secondary bile acids as well as of total bile acids are higher in populations at high risk of colorectal cancer (8, 9). Several case-control studies reported higher levels of secondary bile acids in the feces or sera in patients with colorectal cancer or adenomas as compared with those without these lesions (10-13), but the findings were not replicated in other studies (14-16). A prospective study reported a suggestive increase in the risk of colorectal cancer associated with a high ratio of serum deoxycholic to cholic acids (17). Another epidemiologic evidence is the increased risk of proximal colon cancer in individuals having the gallbladder removed (18, 19). Cholecystectomy results in increased fecal excretion of secondary bile acids, probably due to increase in the bile acid pool in the enterohepatic circulation and increased degradation of primary bile acids in the gut (20, 21).

Recent studies (22, 23), but not all (24), showed that a common genetic polymorphism of cholesterol 7 $\alpha$ -hydroxylase (*CYP7A1 A-203C*) was associated with plasma total and low-density lipoprotein cholesterol concentrations, suggesting lower activity of the enzyme in individuals with the variant C allele. *CYP7A1* is the rate-limiting enzyme in the synthesis of bile acids from cholesterol in the liver, and thus may be an important determinant of not only plasma cholesterol levels but also bile acid production. This article examined the association between the *CYP7A1 A-203C* polymorphism and colorectal cancer in order to further clarify the role of bile acids in colorectal carcinogenesis.

### Materials and Methods

A case-control study was designed to examine the relation of lifestyle factors and genetic susceptibility to the risk of colorectal cancer. Cases were recruited from eight large hospitals in the study area (Fukuoka City and three adjacent areas), and controls were randomly selected in the community by frequency-matching to the distribution of incident cases with respect to sex and 10-year age class. The study protocol was approved

Requests for reprints: Tomoko Hagiwara, Department of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Phone: 81-92-642-6112; E-mail: thagi@med.kyushu-u.ac.jp.  
©2005 American Association for Cancer Research.

by the ethical committees of the Faculty of Medical Sciences, Kyushu University, and of all but two of the participating hospitals. The two hospitals had no ethical committees at the time of survey. Details of the methods have been described elsewhere (25).

**Participants.** Cases were a consecutive series of patients with histologically confirmed incident colorectal adenocarcinomas who were admitted to two university hospitals or six affiliated hospitals for surgical treatment during the period October 2000 to December 2003. Other eligibility criteria were: age of 20 to 74 years at the time of diagnosis, residence in the study area, no prior history of partial or total removal of the colorectum, familial adenomatous polyposis or inflammatory bowel disease, mental competence to give informed consent and to complete the interview. Of 1,053 eligible cases, a total of 840 cases (80%) participated in the interview, and 685 out of them gave an informed consent to genotyping.

Eligibility criteria for controls were the same as described for cases except for the two items, i.e., having no diagnosis of colorectal cancer and age of 20 to 74 years at the time of selection. A total of 1,500 persons were selected as control candidates by two-stage random sampling. The number of control candidates by sex and 10-year age class were determined in accordance to sex- and age-specific numbers of estimated incident cases of colorectal cancer. The first step was a random selection of 15 small areas out of 178 in total, and then ~100 persons were randomly selected in each small area using the municipal resident registry on the basis of proportions of population in the small areas by sex and 10-year age class. A letter of invitation was sent to each candidate, and at most three additional letters of invitation were mailed to nonrespondents. A total of 833 persons participated in the survey, and 778 gave an informed consent to genotyping. The net participation rate was calculated as 60% (833/1,382), after exclusion of 118 persons for the following reasons: death ( $n = 7$ ), migration from the study area ( $n = 22$ ), undelivered mail ( $n = 44$ ), mental incompetence ( $n = 19$ ), history of partial or total removal of the colorectum ( $n = 21$ ), and diagnosis of colorectal cancer after the survey ( $n = 5$ ).

In both cases and controls, older persons and women were less likely to give consent to genotyping, whereas there was no material difference in residence, smoking habit, and alcohol use between individuals giving consent and those who did not (Table 1).

**Procedures.** DNA was extracted from the buffy coat by using a commercial kit (Qiagen GmbH, Hilden, Germany). Genotyping was done by one of the authors (T. Hagiwara) using the PCR-RFLP method. The PCR was done in a reaction mixture of 10  $\mu$ L containing 0.5 units of Taq and 1  $\mu$ L of template DNA with a concentration of ~50 to 150 ng/ $\mu$ L. The *CYP7A1* genotype was determined, as described by Han et al. (24) using primers 5'-AATGT TTTTC CCAGT TCTCT TTC-3' (sense) and 5'-AATTA GCCAT TTGTT CATTC TATTA G-3' (antisense). After the initial denaturation at 94°C for 4 minutes, 30 cycles of PCR were done for 30 seconds at 94°C, for

30 seconds at 53°C, and for 30 seconds at 72°C, with a final extension at 72°C for 7 minutes. The PCR product of 393 bp fragment was digested with 10 units of *BsaI* in a reaction mixture of 20  $\mu$ L for 3 hours at 50°C. The digestion results in fragments of 300 and 93 bp for the *A* allele, and those of 261, 93, and 39 bp for the *C* allele. The digested PCR products were applied to electrophoresis of 3% agarose gel (NuiSieve GTG, Rockland, ME), and visualized by ethidium bromide.

The polymorphism was referred to as *A-204C* by Couture et al. (23), but the actual site of the polymorphism is located 203 bp upstream of the transcription start site according to the latest report of the sequence <http://www.ncbi.nlm.nih.gov/Genomes>). This was also confirmed by our sequencing of the relevant fragment.

**Statistical analysis.** The association of *CYP7A1* genotypes with the risk of colorectal cancer was examined in terms of odds ratio (OR) and 95% confidence intervals (CI). ORs were obtained from multiple logistic regression analysis, including indicator variables for gender, 5-year age class, and resident area (Fukuoka City or suburban area) as covariates. Statistical significance was declared if 95% CI did not include unity. All statistical analyses were done using the SAS version 8.2 (SAS Institute, Inc., Cary, NC).

## Results

Proportions of the *AA*, *AC*, and *CC* genotypes in cases of colorectal cancer were 24%, 56%, and 20%, respectively (Table 2). The corresponding proportions in the control group were 25%, 51%, and 24%, respectively. The distribution in the control group was in agreement with the Hardy-Weinberg equilibrium ( $P = 0.59$ ). The *CC* genotype was slightly less frequent in the case group, and the adjusted OR for the *CC* versus *AA* genotype was slightly lower than unity, with the 95% CI including unity. When the *AA* and *AC* genotypes were combined as the referent, the adjusted OR for the *CC* genotype was 0.81 (95% CI, 0.63-1.04).

The association with *CYP7A1* polymorphism was further examined for cancers of the proximal colon, distal colon, and rectum separately (Table 3). A nearly significant decrease in the OR for the *CC* versus *AA* genotype was observed for proximal colon cancer, but not for the other sites of cancer. When the *AA* and *AC* genotypes were combined as referents, the adjusted ORs of proximal colon cancer for the *CC* genotype was significantly lower than unity.

## Discussion

The present study was the first that examined the relation between a functional *CYP7A1* polymorphism (*A-203C*) and

**Table 1. Characteristics of cases and controls by consent to genotyping**

Variable	Cases			Controls		
	With consent	Without consent	<i>P</i> *	With consent	Without consent	<i>P</i> *
Number	685	155		778	55	
Mean age (y)	60.2	61.9	0.03	58.6	62.9	0.004
Male (%)	62.2	48.4	0.002	63.0	45.5	0.01
Fukuoka City (%)	61.3	57.4	0.37	64.4	67.3	0.67
Ever-smoking (%) <sup>†</sup>	56.3	53.1	0.22	59.7	41.8	0.18
Alcohol use (%) <sup>†,‡</sup>	58.9	55.4	0.22	59.3	45.0	0.33

\**P* values (two-sided) were based on *t* test or  $\chi^2$  test unless otherwise specified.

<sup>†</sup>Adjusted for sex and 5-year age class by the direct method with total number of cases or controls as standard population. *P* values were based on the Mantel-Haenszel method.

<sup>‡</sup>Drinking alcohol at least once per week ~5 years ago.

**Table 2.** Adjusted ORs and 95% CI of colorectal cancer according to CYP7A1 A-203C polymorphisms

CYP7A1 A-203C genotype	Number (%)		Adjusted ORs (95% CI)*
	Cases (n = 685)	Controls (n = 778)	
AA	163 (24)	193 (25)	1.00 (referent)
AC	385 (56)	399 (51)	1.13 (0.88-1.46)
CC	137 (20)	186 (24)	0.88 (0.65-1.20)

\*Adjusted for gender, 5-year age class, and resident area.

colorectal cancer, and showed a decreased risk of cancer of the proximal colon, but not of the distal colon and rectum, among individuals having the CC genotype. This genotype is probably associated with lowered capability of synthesizing bile acids (22, 23), the findings provide further evidence to the role of bile acids in colorectal carcinogenesis.

An advantage in this large-scale case-control study is that controls were derived from free-living residents in the community. It is also notable that participation rates of eligible cases and controls were fairly high. Genotyping was done in 82% of the cases and 93% of the controls who participated in the survey. It is generally considered that selection and confounding are less likely to occur in studies of genetic polymorphisms (26, 27). It is, however, possible that use of hospital controls may cause selection bias even in the gene-disease association. For instance, individuals with high blood cholesterol levels may have been included or excluded differentially in the controls if selection had occurred in patients with cholesterol-related diseases. The study subjects were an ethnically homogenous population of Japanese, and the concern over population stratification would be negligible (28).

Since the first report by Rose et al. (29), many prospective studies have observed an inverse association between serum total or low-density lipoprotein cholesterol and colon cancer (30). Although this inverse association is generally ascribed to the effect of preclinical cancer existing at the baseline (30), an increased risk of proximal colon cancer associated with low levels of serum total cholesterol persisted 10 to 20 years later in a

prospective study in Hawaii (31). Furthermore, a case-control study observed lower levels of total and low-density lipoprotein cholesterol in cases of proximal colon cancer, but not of distal colon cancer, than in controls (32). These findings are congruent with decreased risk of proximal colon cancer associated with the CYP7A1 CC genotype.

High-fat diets are shown to increase fecal excretion of secondary bile acids as well as of total bile acids in humans (33), and to enhance chemically induced colon carcinogenesis in animals (34). Although fat intake is strongly positively correlated with colon cancer rates among countries (35), and over time in Japan (36), studies of individuals have consistently failed to find a positive association between fat intake and colon or colorectal cancer (37). The lack of an association with fat in studies of individuals may be due to a limited variation of fat intake within populations. In this regard, the present findings emphasize the usefulness of studying functional genetic polymorphisms when study populations are homogeneous with respect to exposure to environmental factors such as nutrient and food intake.

In conclusion, a large case-control study in Japan showed a decreased risk of proximal colon cancer in individuals having the CC genotype of CYP7A1 A-203C, which probably renders less activity of the enzyme converting cholesterol to bile acids. The findings add to evidence for the role of bile acids in colorectal carcinogenesis.

## Acknowledgments

Received 10/28/2004; revised 12/21/2004; accepted 1/19/2005.

**Grant support:** Grant-in-Aid for Scientific Research on Priority Areas (12218226) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Emeritus Professor Keizo Sugimachi; Professors Seiyo Ikeda, Takayuki Shirakusa, and Sumitaka Arima; and Drs. Motonori Saku, Yoichi Ikeda, Soichiro Maekawa, Kazuo Tanoue, Kinjiro Sumiyoshi, and Shoichiro Saito in conducting the survey of cases. The following physicians kindly supervised the survey of controls at their clinics: Drs. Hideaki Baba, Tomonori Endo, Hiroshi Hara, Yoichiro Hirokawa, Motohisa Ikeda, Masayoshi Ishibashi, Fumiaki Itoh, Yasuhiro Iwanaga, Hideki Kaku, Shoshi Kaku, Minoru Kanazawa, Akira Kobayashi, Ryunosuke Kumashiro, Shinichi Matsumoto, Soukei Mioka, Umeji Miyakoda, Osamu Nakagaki, Nobuyoshi Nogawa, Nobuyuki Ogami, Toyooki Okabayashi, Hironao Okabe, Nishiki Saku, Masafumi Tanaka, Masahiro Ueda, Bunichi Ushio, and Koheisho Yasunaga. The authors are grateful to research nurses Nobuko Taguchi, Yuriko Moroe, Yuko Noda, Ryoko Tanaka, Hisako Nakagawa, and Yoko Mikasa and research clerk Hiroko Mizuta for their self-sacrificing work.

**Table 3.** Adjusted OR and 95% CI of colorectal cancer according to CYP7A1 A-203C genotypes by subsite

CYP7A1 A-203C genotype	Proximal colon (n = 150)		Distal colon (n = 232)		Rectum (n = 290)	
	No.	OR (95% CI)*	No.	OR (95% CI)*	No.	OR (95% CI)*
<b>Model 1</b>						
AA	39	1.00 (referent)	52	1.00 (referent)	69	1.00 (referent)
AC	88	1.09 (0.71-1.65)	129	1.18 (0.81-1.70)	159	1.09 (0.78-1.53)
CC	23	0.63 (0.36-1.10)	51	1.01 (0.65-1.57)	62	0.93 (0.62-1.39)
<b>Model 2</b>						
AA + AC	127	1.00 (referent)	181	1.00 (referent)	228	1.00 (referent)
CC	23	0.59 (0.37-0.96)	51	0.90 (0.63-1.29)	62	0.87 (0.63-1.22)

\*Adjusted for gender, 5-year age class, and resident area.

## References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. *Int J Cancer* 2001;94:153-6.
2. Kono S. Dietary factors for gastrointestinal cancers: a worldwide overview. *Gann Monogr Cancer Res* 1996;44: 29-39.
3. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. *Cancer incidence in five continents, Vol. VIII, IARC Scientific Publications, No. 155*. IARC, Lyon; 2002.
4. Narisawa T, Magadia NE, Weisburger JH, Wynder EL. Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine in rats. *J Natl Cancer Inst* 1974;53: 1093-7.
5. Reddy BS, Narasawa T, Weisburger JH, Wynder EL. Promoting effect of sodium deoxycholate on colon adenocarcinomas in germ-free rats. *J Natl Cancer Inst* 1976;56:441-2.
6. Qiao D, Chen W, Stratagoulis ED, Martinez JD. Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. *J Biol Chem* 2000;275:15090-8.
7. Milovic V, Teller IC, Faust D, Caspary WF, Stein J. Effects of deoxycholate on human colon cancer cells: apoptosis or proliferation. *Eur J Clin Invest* 2002;32:29-34.
8. Reddy BS, Wynder EL. Large-bowel carcinogenesis: fecal constituents of populations with diverse incidence rates of colon cancer. *J Natl Cancer Inst* 1973; 50:1437-42.
9. Wynder EL, Reddy BS. Metabolic epidemiology of colorectal cancer. *Cancer* 1974;34:801-6.
10. Hill MJ, Drasar BS, Williams RE, et al. Faecal bile-acids and clostridia in patients with cancer of the large bowel. *Lancet* 1975;1:535-9.
11. Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. *Cancer* 1977;39:2533-9.
12. Bayerdörffer E, Mannes GA, Richter WO, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. *Gastroenterology* 1993;104:145-51.
13. Bayerdörffer E, Mannes GA, Ochsenkühn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. *Gut* 1995;36:268-73.
14. Blackwood A, Murray WR, Mackay C, Calman KC. Fecal bile acids and clostridia in the aetiology of colorectal and breast cancer. *Br J Cancer* 1978;38:175.
15. Mudd DG, McKelvey ST, Norwood W, Elmore DT. Carcinoma of the large bowel and faecal bile acids. *Br J Surg* 1979;66:355.
16. Murray WR, Blackwood A, Calman KC, Mackay C. Faecal bile acids and clostridia in the aetiology of colorectal cancer. *Br J Surg* 1979;66:364.
17. Costarelli V, Key TJ, Appleby PN, Allen DS, Fentiman IS, Sanders TA. A prospective study of serum bile acid concentrations and colorectal cancer risk in post-menopausal women on the island of Guernsey. *Br J Cancer* 2002;86:174-4.
18. Giovannucci E, Colditz GA, Stampfer MJ. A meta-analysis of cholecystectomy and risk of colorectal cancer. *Gastroenterology* 1993;105:130-41.
19. Reid FD, Mercer PM, Harrison M, Bates T. Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis. *Scand J Gastroenterol* 1996;31:160-9.
20. Pomare EW, Heaton KW. The effect of cholecystectomy on bile salt metabolism. *Gut* 1973;14:753-62.
21. Hepner GW, Hofmann AF, Malagelada JR, Szczepanik PA, Klein PD. Increased bacterial degradation of bile acids in cholecystectomized patients. *Gastroenterology* 1974;66:556-64.
22. Wang J, Freeman DJ, Grundy SM, Levine DM, Guerra R, Cohen JC. Linkage between cholesterol 7 $\alpha$ -hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. *J Clin Invest* 1998;101:1283-91.
23. Couture P, Otvos JD, Cupples LA, Wilson PW, Schaefer EJ, Ordovas JM. Association of the A-204C polymorphism in the cholesterol 7 $\alpha$ -hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. *J Lipid Res* 1999;40:1883-9.
24. Han Z, Heath SC, Shmulewitz D, et al. Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, Federated States of Micronesia. *Am J Med Genet* 2002;110:234-42.
25. Kono S, Toyomura K, Yin G, Nagano J, Mizoue T. A case-control study of colorectal cancer in relation to lifestyle factors and genetic polymorphisms: design and conduct of the Fukuoka colorectal cancer study. *Asian Pac J Cancer Prev* 2004;5:393-400.
26. Smith DG, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* 2003;32:1-22.
27. Wheatley K, Gray R. Mendelian randomization—an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. *Int J Epidemiol* 2004;33: 15-7.
28. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. *Lancet* 2003;361:598-604.
29. Rose G, Blackburn H, Keys A, et al. Colon cancer and blood-cholesterol. *Lancet* 1974;1:181-3.
30. Law MR, Thompson SG. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. *Cancer Causes Control* 1991;2:253-61.
31. Nomura AM, Stemmermann GN, Chyou PH. Prospective study of serum cholesterol levels and large-bowel cancer. *J Natl Cancer Inst* 1991;83:1403-7.
32. Kervinen K, Södervik H, Mäkelä J, et al. Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? *Gastroenterology* 1996;110:1785-90.
33. Reddy BS. Diet and excretion of bile acids. *Cancer Res* 1981;41:3766-8.
34. Reddy BS. Dietary fat and colon cancer: animal model studies. *Lipids* 1992;27:807-13.
35. McKeown-Eyssen GE, Bright-See E. Dietary factors in colon cancer: international relationships. *Nutr Cancer* 1984;6:160-70.
36. Kono S. Secular trend of colon cancer incidence and mortality in relation to fat and meat intake in Japan. *Eur J Cancer Prev* 2004;13:127-32.
37. World Cancer Research Fund and American Institute for Cancer Research. *Food, nutrition and the prevention of cancer: a global perspective*. Washington, DC: American Institute for Cancer Research; 1997.



独立行政法人国立病院機構九州がんセンター消化器外科

藤<sup>\*</sup>也寸志 伊藤 修平 足立 英輔 田中 真二 大賀 丈史  
坂口 善久 椛島 章 山本 一治 原口 勝 岡村 健

臨 床 外 科

第60巻 第11号(増刊号) 別刷

2005年10月22日 発行

医学書院

# 胃癌治療のプロトコール

藤 也寸志  
坂口 善久

伊藤 修平  
梶島 章

足立 英輔  
山本 一治

田中 真二  
原口 勝

大賀 文史  
岡村 健

## はじめに

当科では、原則として外来での精査を行い、入院後の術前・術後診療についてはクリニカルパスを使用している。また、胃癌治療の基本的なプロトコールは「胃癌治療ガイドライン」<sup>1)</sup>に則っている。

## 術前診断のプロトコール

### 1. 術前患者の評価

#### 1) 全身状態の評価

当院では外来初診時に問診表を配り、患者自身に現病歴、既往歴、家族歴などを記入してもらっている。また90%が紹介患者であり、紹介医からの情報もあるため、診察前に多くの情報を得ることができる。それらを参考にしながら再度の十分な問診に加えて、腹部触診、胸腹部の聴診、表在リンパ節腫大・貧血・浮腫の有無などの身体所見にて患者の全身状態を把握する。特に進行胃癌の場合、腹痛、食物の通過障害や栄養状態、出血の有無などを把握し、緊急入院の必要性が高いか否かを判断するように心掛けている。入院の緊急性が低い患者には、一般に外来で全身状態の評価を行っている。血液型、感染症の有無（患者の同意を得たうえで、梅毒、B型肝炎ウイルス、C型肝炎ウイルス、HIVのチェックを施行する）、心・肺・肝・腎機能、検尿、凝固能、電解質、栄養状態、耐糖能などの評価、胸腹部X線検査を初診時

に終えるようにしている。

既往歴や外来検査の結果で他科の受診が必要な場合は、可能な限り入院前にチェックするようにしている。特に70歳以上の高齢者や心電図上異常が認められた場合には、循環器専門医による心機能評価を行っている。術前に血糖、血圧、貧血などのコントロールが必要な場合は、早めに入院して術前のコントロールを行う。したがって、既往症のない患者の入院は手術日の3~4日前に入院となる。入院後の主治医が外来担当医と異なる場合もあるため、入院までは外来担当医が責任を持って検査結果などをチェックして必要な検査を追加するなど、入院前の患者の状況を十分に把握しておくことが肝要である。

#### 2) 胃癌の進行度の評価

上部消化管造影検査と上部消化管内視鏡検査により、胃癌病巣の肉眼型、大きさ、部位、深達度を評価する。主病巣のみならず、胃内に副病巣、多発病巣がないかを十分に検索することも重要である。縮小手術が考慮される場合には、さらに超音波内視鏡検査を行い、深達度とリンパ節転移の有無を評価する。癌病巣が食道胃接合部に近いときや術中触診上、腫瘍の口側縁の同定が困難であると予想されるときは、口側切除線の設定のために内視鏡時にstep biopsyを行い、さらに腫瘍口側のクリッピングによるマーキングを施行している。

遠隔転移や周囲組織への浸潤を検索するため

に、胸部 X 線単純撮影、腹部骨盤 CT、腹部骨盤 US は必須である。進行癌の場合には、さらに胸部 CT、骨シンチグラムを追加する。周囲組織へ直接浸潤が疑われるときには MRI を追加する。また大腸病変の合併例も多く、腹膜播種のチェックの目的も合わせて、全例に注腸検査または大腸内視鏡検査を併施している。

腫瘍マーカーとして、CEA、CA19-9、CA125、STN をルーチンで測定している。

## 2. インフォームド・コンセント

多くの患者がすでに紹介医から癌の告知を受けている場合が多いが、外来初診時に患者自身の告知に対する意思の確認を文書を用いて行っている。当院ではがんセンターであるという特殊性もあり、ほぼ 100% が癌の告知を希望されている。最近では本人が希望する場合、告知はまず本人に行い、ついで本人の同意がある家族に対して行うという方向にある。

外来では説明のための十分な時間を確保することが困難な場合が多く、患者の社会的背景や性格などの把握が不十分になりやすい。そのため病状（胃癌の進行度）や治療方針の説明は、入院して主治医が十分な時間をとって、家族同席のうえで行っている。高度進行胃癌で予後がきわめて厳しい場合でも、ありのままを話すように心掛けている。インフォームド・コンセントは画一的なものであってはならず、個々の患者に最もふさわしいと思える方法で行うという姿勢が重要である。また、告知のあとの精神的サポートを、医師のみならずスタッフ全員で行う必要がある。患者が希望する場合は、サイコオンコロジー科医師へのコンサルテーションが行われる。

治療についての説明の際には、画像の呈示に加えて癌の深達度や術式などさまざまな図を利用して、可能な限り平易な言葉を使用するように心掛けている。その際には、(1) 病名と病状・進行度、(2) 治療の必要性和提案する治療法の詳細、(3) 予測される治療の効果と予後、(4) 生じうる合併症・危険性、(5) そのほかの治療法について説明する。特に胃癌手術の場合、進行度や部位に応じた切除範囲やリンパ節郭清範囲、再建術式、さら

に胃切除による術後の障害なども含めて十分に説明することが大切である。これらの説明に際しては、説明の理解・納得のための十分な時間を持つように、説明内容を詳細に記載した文書を承諾書として手渡して、1~2 日間再確認してもらったのちに、署名した承諾書として提出してもらっている。

## 3. 術前治療・処置

進行胃癌の場合、経口摂取不良による低栄養状態、脱水、電解質異常や貧血がある場合がしばしばある。その場合は早期に入院として、中心静脈栄養を行い栄養状態の改善をはかる。特に狭窄が強い場合には、絶飲食として中心静脈栄養を行う。鉄剤投与により貧血の改善をはかるが、術直前に Hb 10 g/dl 以下のときには輸血を行う。

心電図異常や心疾患の既往がある患者に対しては、循環器専門医による評価を行う。ときにはペースメーカー留置や冠動脈ステント挿入などを優先することもある。そのほか、糖尿病がある場合のインスリンによるコントロール、腎機能障害に対する腎血流改善処置なども必要である。

当院では、手術によって根治度 B が得られると判断された場合には、術前化学療法は行っていない。腹膜播種症例、高度リンパ節転移症例、遠隔臓器転移症例など根治切除が不可能な場合、主として TS-1 を中心とした化学療法を行い、効果がみられた場合には手術に移行することもある。

## 手術のプロトコール

胃癌の占居部位、大きさ、深達度別にリンパ節転移の詳細な実態が明らかになっている<sup>1)</sup>。それらを根拠として、第一に根治性を最重要視しながら、可及的に機能温存を目指した縮小手術を導入している。一方では、進行胃癌に対する化学療法での完治が困難な現状では、患者の十分な理解を得たうえで、拡大手術を積極的に行っている。

### 1. 内視鏡的粘膜切除術 (EMR)

「胃癌治療ガイドライン」<sup>1)</sup>に準じて、EMR の適応は、原則として分化型の粘膜内癌で隆起型、陥凹型（潰瘍、瘢痕を伴わないもの）ともに 2 cm 以下の病変と定めている。低分化型胃癌や潰瘍（瘢

痕)を伴う胃癌はEMRの適応から除外している。超高齢者や重篤な合併症を有する場合は、適応を拡大することもある。水平方向に癌遺残が疑われる場合は再EMRや焼灼術を追加し、sm1を超える場合や脈管侵襲がある場合にはリンパ節郭清を伴う胃切除術を行う。

上記の適応を満たすが、胃上部の癌で部位的にEMRが困難な場合、小開腹下に内視鏡を胃体部大彎側より挿入してEMRを行うこともある(図1)<sup>2)</sup>。

## 2. 縮小手術

胃局所切除は、鉄やビタミンB<sub>12</sub>吸収障害による貧血も少なく、残胃の内視鏡検査も可能であるという長所がある反面、根治性が劣る可能性があるため、適応には慎重であるべきである。早期胃癌におけるリンパ節転移の検討では、深達度(組織学的)Mでは4%前後であるのに対して、(組織学的)SMでは20%以上で無視できない頻度である<sup>1,3)</sup>。また、病理学的に転移陽性リンパ節を検討した結果では、術中肉眼判定での正診率は21.4%であり、術中に肉眼的にリンパ節転移の有無を判断するのは困難である<sup>3)</sup>。このため縮小手術としての胃局所切除の適応は、EMRの適応外である胃上中部の深達度Mの早期胃癌としている。大きさは病変の部位によっても異なるが、大きな変形を残さず、かつ腫瘍縁より十分な距離を持って切除しようと考えられる約3cmまでの病変としている。

また最近では、幽門側胃切除術が可能な部位にあるSMまでの早期癌に対して、手術侵襲の軽減をはかる目的で、腹腔鏡補助下幽門側切除術(LADG)を縮小手術として取り入れている。リンパ節は、1群+βあるいは2群までの郭清が可能である。

## 3. 定型的胃切除術(幽門側胃切除術, 胃全摘術)

「胃癌治療ガイドライン」<sup>1)</sup>に準じ、他臓器浸潤がなく(T3以下)、D2郭清で根治度A、Bが期待できる症例に対しては、幽門側胃切除術、胃全摘術を施行している。腫瘍占拠部位がLまたはM領域に局限している病変に対しては、幽門側胃切除術を行う。腫瘍占拠部位がU領域あるいはM領




図1 胃体上部早期癌に対するEMR

域、L領域でも胃上部にまで進展している進行胃癌の場合、腫瘍口側縁から食道胃接合部までの距離が限局型で4cm、浸潤型で6cm確保できないときや、噴門部リンパ節(1番, 2番)に明らかな転移があるときは胃全摘術を施行している。

胃上部早期癌に対しては胃局所切除、噴門側胃切除術、胃全摘術があり得るが、それぞれの長所と欠点を表にして患者に十分説明し選択してもらっている(図2)。当施設では胃全摘術が選択されることが多い。

定型の手術(幽門側胃切除術, 胃全摘術)の場合は、2群のリンパ節郭清を施行している。また、迷走神経前幹より分枝する肝枝の温存が、術後胆嚢炎発生の減少に貢献するという報告があるため<sup>4)</sup>、T2までで1番リンパ節の腫大がなければ、幽門側胃切除の場合は可及的にそれを温存している。迷走神経肝枝を温存してもD2郭清は可能である。

当施設で胃上中部のT2, T3進行癌に対する脾門部リンパ節郭清のための脾合併切除の適応を検討した結果、T3症例またはT2で7個以上のリンパ節転移陽性症例、癌占拠部位が大彎である症例においては脾門部リンパ節転移陽性率が高く、脾合併切除の適応であると考えている(表1, 2)<sup>5)</sup>。